Short answer
Since 1 July 2026, yes, for some people. Under the Medicare GLP-1 Bridge, eligible Part D members who meet the BMI and health-condition criteria pay a $50 copay for Wegovy (injection or pill), Zepbound KwikPen and Foundayo. The program runs to 31 December 2027. Before it, Medicare was barred from covering drugs for weight loss alone.
What changed
For years federal law kept Medicare Part D from paying for weight-loss drugs, though it could cover Wegovy for heart-risk reduction and Ozempic or Mounjaro for diabetes. The Medicare GLP-1 Bridge, announced in May 2026 and live from 1 July 2026, is a temporary program that adds coverage for obesity treatment itself, at a fixed $50 monthly copay, through the end of 2027.
Who qualifies
You need to be an eligible Part D beneficiary and meet body-mass-index and related-condition thresholds set by the program. The covered products are Wegovy, in both injection and tablet form, Zepbound in the KwikPen, and Foundayo. Your prescriber and your Part D plan confirm eligibility; medicare.gov has the current rules.
If you don’t qualify
The makers’ own self-pay prices are the fallback. Lilly’s LillyDirect lists Zepbound at $299 to $449 a month and says Medicare Part D members pay no more than $50 for Foundayo. Novo’s NovoCare lists Wegovy at $199 for the first two intro months, then $349, and the pill at $149 to $299. People with commercial insurance may get the makers’ savings cards, which don’t apply to government plans.
Related questions
Does Medicare cover Ozempic?
For type 2 diabetes, yes, under Part D as before. The Bridge program is specifically about obesity treatment.
Is the Bridge permanent?
No. It is scheduled to run from 1 July 2026 to 31 December 2027. What follows hasn’t been decided.
Read next
Sources
Published 2026-09-30 · Last checked 2026-09-30
Educational content, not medical advice. Made for the United States.